Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL237659 | 1.00 | GSR (0.54) | GSRCPB2ITGB3ITGA2BDPP7 | |
| Lysine SCHEMBL2100363 | 0.84 | GSR (0.62) | GSRCPB2ITGB3ITGA2BDPP7 | |
| Lysine SCHEMBL2369399 | 0.84 | GSR (0.62) | GSRCPB2ITGB3ITGA2BDPP7 | |
| Glutamic Acid SCHEMBL3738402 | 0.83 | CYP1A2 (0.51) | GSRDPP7DPP4DPP8FAP | |
| D-Glutamate SCHEMBL4777197 | 0.83 | CYP1A2 (0.51) | GSRDPP7DPP4DPP8FAP | |
| Arginine SCHEMBL15110976 | 0.81 | OTC (0.39) | — | |
| Glutamine SCHEMBL3974114 | 0.81 | BLM (0.47) | GSRDPP4DPP8DPP9 | |
| Leucine SCHEMBL6369626 | 0.80 | SLC7A5 (0.55) | DPP7DPP4DPP8DPP9 | |
| Leucine SCHEMBL6369629 | 0.80 | SLC7A5 (0.55) | DPP7DPP4DPP8DPP9 | |
| Glycine SCHEMBL10447054 | 0.79 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 427 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498289-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2019-06-19 | — | — | EP | claimed |
| EP-2722051-B1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | SEATTLE GENETICS INC (US) | 2018-11-07 | — | — | EP | claimed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | claimed |
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703714-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-8512707-B2 | Methods of treating drug-resistant cancers | SEATTLE GENETICS, INC. (US) | 2013-08-20 | — | — | US | claimed |
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| US-20100260786-A1 | METHODS OF TREATING DRUG-RESISTANT CANCERS | SEATTLE GENETICS, INC. (US) | 2010-10-14 | — | — | US | claimed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007137170-A2 | ANTI-GLYPICAN-3 ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007103288-A2 | ENGINEERED ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| CN-1938046-A | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC (US) | 2007-03-28 | — | — | CN | claimed |
| WO-2007008848-A2 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| EP-1725249-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seattle Genetics, Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2005-10-27 | — | — | US | claimed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| CN-113677364-B | Pharmaceutical compositions comprising anti-191P 4D12 antibody drug conjugates and methods of use thereof | 艾更斯司股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118271442-A | Anti-SEZ 6L2 antibodies and antibody drug conjugates | 蓝鳍生物医药公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-110234348-B | Anti-CUB domain-containing protein 1 (CDCP 1) antibodies, antibody drug conjugates, and methods of use thereof | 蓝鳍生物医药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11981732-B2 | Anti-TMEFF1 antibodies and antibody drug conjugates | BLUEFIN BIOMEDICINE, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-04-25 | — | — | US | disclosed |
| CN-110121507-B | anti-SEZ 6L2 antibodies and antibody drug conjugates | 蓝鳍生物医药公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11932694-B2 | Anti-VTCN1 antibodies and antibody drug conjugates | BLUEFIN BIOMEDICINE, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240084032-A1 | ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF | BLUEFIN BIOMEDICINE, INC. | 2024-03-14 | — | — | US | disclosed |
| CN-117642185-A | Improved CD30 targeting antibody drug conjugates and uses thereof | 路德维希-马克西米利安慕尼黑大学 | 2024-03-01 | — | — | CN | disclosed |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | disclosed |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | disclosed |
| CN-110845615-B | Anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230331839-A1 | ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-10-17 | — | — | US | disclosed |
| US-20230270871-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | AGENSYS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-4218929-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-109963870-B | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-110841074-B | anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11702481-B2 | Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof | BLUEFIN BIOMEDICINE, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-116284404-A | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230192885-A1 | ANTI-LY6H ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-116209464-A | Markers for use in methods of treating cancer with Antibody Drug Conjugates (ADCs) | 艾更斯司股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116173232-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-2874651-B1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-05-24 | — | — | EP | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4168039-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | Agensys, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11634486-B2 | Anti-SEZ6L2 antibodies and antibody drug conjugates | BLUEFIN BIOMEDICINE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11633500-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | AGENSYS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11633494-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | disclosed |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11607460-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4148069-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2023-03-15 | — | — | EP | disclosed |
| US-20230069760-A1 | ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230038373-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2023-02-09 | — | — | US | disclosed |
| US-20230033859-A1 | CD19 BINDING AGENTS AND USES THEREOF | SEAGEN INC (US) | 2023-02-02 | — | — | US | disclosed |
| US-20230025600-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-11559582-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115611988-A | Compounds for targeted immunotherapy | 博笛生物科技有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-109562170-B | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20230001005-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220389113-A1 | BINDING PROTEINS TO CUB DOMAIN-CONTAINING PROTEIN (CDCP1) | COMMW SCIENT IND RES ORG (AU) | 2022-12-08 | — | — | US | disclosed |
| CN-115397473-A | Treatment of cancer with Antibody Drug Conjugates (ADC) capable of binding 191P4D12 protein | 艾更斯司股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220298239-A1 | ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220288221-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-09-15 | — | — | US | disclosed |
| US-11434303-B2 | Anti-LY6H antibodies and antibody drug conjugates | BLUEFIN BIOMEDICINE, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| CN-114901690-A | Treatment of cancer with Antibody Drug Conjugates (ADCs) that bind 191P4D12 protein | 艾更斯司股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220227863-A1 | ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. | 2022-07-21 | — | — | US | disclosed |
| CN-114716555-A | Compounds and compositions for targeting EGFR expressing tumors | 博笛生物科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
| EP-4013795-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220175950-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3092256-B1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-05-18 | — | — | EP | disclosed |
| US-11331394-B2 | CD19 binding agents and uses thereof | SEAGEN INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11312769-B2 | Anti-TMEFF1 antibodies and antibody drug conjugates | BLUEFIN BIOMEDICINE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11248054-B2 | Anti-IL1RAP antibodies and antibody drug conjugates | BLUEFIN BIOMEDICINE, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-02-03 | — | — | US | disclosed |
| US-20210402002-A1 | CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-12-30 | — | — | US | disclosed |
| WO-2021257938-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | AGENSYS, INC, (US) | 2021-12-23 | — | — | WO | disclosed |
| CN-113677364-A | Pharmaceutical compositions comprising anti-191P 4D12 antibody drug conjugates and methods of use thereof | 艾更斯司股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-113633783-A | Compounds and compositions for immunotherapy | 博笛生物科技有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-105899539-B | Compounds and compositions for immunotherapy | 博笛生物科技有限公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-3903812-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3890778-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | Agensys, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210312797-A9 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-11130812-B2 | Anti PD-L1 conjugates for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-09-28 | — | — | US | disclosed |
| US-20210283268-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| EP-3858387-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seagen Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11072662-B2 | Humanized anti-CLL-1 antibodies | CELLERANT THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3409287-B9 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS INC (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021123506-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-06-24 | — | — | WO | disclosed |
| EP-3835322-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021108353-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210145979-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | AGENSYS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210138080-A1 | CONJUGATES | GLYKOS BIOMEDICAL OY (FI) | 2021-05-13 | — | — | US | disclosed |
| US-20210130454-A1 | ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-3813883-A1 | CONJUGATES | Glykos Biomedical Oy (FI) | 2021-05-05 | — | — | EP | disclosed |
| EP-3810204-A1 | CONJUGATE | Glykos Biomedical Oy (FI) | 2021-04-28 | — | — | EP | disclosed |
| EP-3409287-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS INC (US) | 2021-04-07 | — | — | EP | disclosed |
| CN-112587672-A | anti-PD-L1 conjugates for the treatment of tumors | 博笛生物科技有限公司 | 2021-04-02 | — | — | CN | disclosed |
| US-20210095043-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| CN-112546238-A | anti-PD-L1 conjugates for the treatment of tumors | 博笛生物科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210074147-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-10941211-B2 | Anti-GCC antibody molecules and related compositions and methods | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| WO-2021030240-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-10894090-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3763742-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2021-01-13 | — | — | EP | disclosed |
| US-RE48389-E1 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200405878-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200353093-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-11-12 | — | — | US | disclosed |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200345860-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200308298-A1 | ANTI-LY6H ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10780180-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-09-22 | — | — | US | disclosed |
| US-20200276327-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HER2 POSITIVE TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3189082-B1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2020-08-19 | — | — | EP | disclosed |
| US-10744206-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-08-18 | — | — | US | disclosed |
| US-20200246478-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-08-06 | — | — | US | disclosed |
| CN-111378041-A | anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111330017-A | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | 艾更斯司股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-111330016-A | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | 艾更斯司股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-20200179527-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200181281-A1 | ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF | BLUEFIN BIOMEDICINE, INC. | 2020-06-11 | — | — | US | disclosed |
| WO-2020117373-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-10669348-B2 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | AGENSYS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10660971-B2 | Compounds for targeted immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-05-26 | — | — | US | disclosed |
| CN-106563128-B | Use of auristatin-based antibody drug conjugates and mTOR-binding inhibitors in the manufacture of a medicament for the treatment of cancer | 西雅图遗传学公司 | 2020-05-22 | — | — | CN | disclosed |
| US-20200155700-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING EGFR EXPRESSING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-05-21 | — | — | US | disclosed |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
| US-10646583-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | AGENSYS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200140561-A1 | ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-04-23 | — | — | US | disclosed |
| EP-3638697-A1 | ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | Bluefin Biomedicine, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| CN-110997725-A | anti-IL 1RAP antibodies and antibody drug conjugates | 蓝鳍生物医药公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20200109194-A1 | ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| CN-110845615-A | anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2020-02-28 | — | — | CN | disclosed |
| CN-110845616-A | anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2020-02-28 | — | — | CN | disclosed |
| CN-110841074-A | anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2020-02-28 | — | — | CN | disclosed |
| EP-3612567-A1 | ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | Bluefin Biomedicine, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-2490720-B1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARM INC (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3601360-A1 | ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | Bluefin Biomedicine, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10548988-B2 | Compounds for targeted immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-02-04 | — | — | US | disclosed |
| US-10548985-B2 | Compounds and compositions for treating EGFR expressing tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-02-04 | — | — | US | disclosed |
| US-20200031926-A1 | ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2020-01-30 | — | — | US | disclosed |
| CN-105073132-B | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | 艾更斯司股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| WO-2020002765-A1 | CONJUGATES | GLYKOS BIOMEDICAL OY (FI) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019243672-A1 | CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2019-12-26 | — | — | WO | disclosed |
| CN-106459200-B | anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2019-12-06 | — | — | CN | disclosed |
| US-20190338045-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2019-11-07 | — | — | US | disclosed |
| US-20190328898-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS INC (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3559043-A1 | ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | Bluefin Biomedicine, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| CN-105567717-B | It is incorporated into the antibody drug conjugates (ADC) of 191P4D12 albumen | Algens Co.,Ltd. (US) | 2019-10-29 | — | — | CN | disclosed |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| CN-110234348-A | anti-CUB domain containing protein 1(CDCP1) antibodies, antibody drug conjugates, and methods of use thereof | 蓝鳍生物医药公司 | 2019-09-13 | — | — | CN | disclosed |
| US-20190269789-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2019-09-05 | — | — | US | disclosed |
| US-20190269790-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2019-09-05 | — | — | US | disclosed |
| CN-110121507-A | anti-SEZ 6L2 antibodies and antibody drug conjugates | 蓝鳍生物医药公司 | 2019-08-13 | — | — | CN | disclosed |
| EP-3520816-A2 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | Millennium Pharmaceuticals, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-110054692-A | Anti- GCC antibody molecule and its compositions related and method | 米伦纽姆医药公司 | 2019-07-26 | — | — | CN | disclosed |
| EP-3505191-A1 | AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS | Seattle Genetics, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| CN-109963870-A | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | 艾伯维公司 | 2019-07-02 | — | — | CN | disclosed |
| US-10328158-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2019-06-25 | — | — | US | disclosed |
| US-20190184029-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC. | 2019-06-20 | — | — | US | disclosed |
| EP-3498289-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3494996-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | Agensys, Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| CN-105722534-B | In conjunction with the antibody drug conjugates (ADC) of CD37 albumen | 艾更斯司股份有限公司 | 2019-05-31 | — | — | CN | disclosed |
| US-20190153110-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC (US) | 2019-05-23 | — | — | US | disclosed |
| EP-2629801-B1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEATTLE GENETICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190134216-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190127482-A1 | CONJUGATES OF SURROGATE LIGHT CHAIN CONSTRUCTS | REVOPSIS HOLDINGS, LLC | 2019-05-02 | — | — | US | disclosed |
| US-10273299-B2 | Antibodies to tumor endothelial marker 8 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3468599-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468993-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468596-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468598-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3469000-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| CN-105102480-B | Prolactin receptor binding proteins and uses thereof | 艾伯维公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109641962-A | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109563167-A | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | 艾伯维公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109562168-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109562170-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109562169-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-3458479-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10226535-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2928503-B1 | CONJUGATES OF AURISTATIN COMPOUNDS | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10201615-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEATTLE GENETICS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| EP-3434275-A1 | ASSAY FOR CANCER CELLS BASED ON THE USE OF AURISTATIN CONJUGATES WITH ANTIBODIES | Seattle Genetics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-10184003-B2 | Prolactin receptor binding proteins and uses thereof | ABBVIE INC. (US) | 2019-01-22 | — | — | US | disclosed |
| EP-1817336-B1 | AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS | SEATTLE GENETICS INC (US) | 2019-01-09 | — | — | EP | disclosed |
| WO-2019006162-A1 | ANTI-LY6H ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2018231827-A1 | ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| EP-2887959-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180355062-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-12-13 | — | — | US | disclosed |
| US-20180355044-A1 | HUMANIZED ANTI-CLL-1 ANTIBODIES | CELLERANT THERAPEUTICS, INC. (US) | 2018-12-13 | — | — | US | disclosed |
| EP-3409287-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180326087-A1 | CD19 BINDING AGENTS AND USES THEREOF | SEAGEN INC. | 2018-11-15 | — | — | US | disclosed |
| EP-2722051-B1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | SEATTLE GENETICS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3395361-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | Agensys, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-RE47103-E1 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | AGENSYS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| WO-2018195302-A1 | ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180296693-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | SEAGEN INC. | 2018-10-18 | — | — | US | disclosed |
| US-10098968-B2 | Anti-EGFR antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3380524-A1 | HUMANIZED ANTI-CLL-1 ANTIBODIES | Cellerant Therapeutics, Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| WO-2018175740-A1 | ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| US-20180251566-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | SEAGEN INC. | 2018-09-06 | — | — | US | disclosed |
| US-20180243439-A1 | Pharmaceutical Formulation of an Anti-Guanylyl Cyclase C Antibody Conjugate Comprising Histidine or a Salt Thereof and Polysorbate 20 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180236096-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | AGENSYS, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3363817-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | AbbVie Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2018148494-A1 | ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| CN-108290955-A | The anti-CLL-1 antibody of humanization | 塞勒兰特治疗公司 | 2018-07-17 | — | — | CN | disclosed |
| WO-2018119351-A1 | ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180177888-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH INC. (CN) | 2018-06-28 | — | — | US | disclosed |
| US-20180177887-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH INC. (CN) | 2018-06-28 | — | — | US | disclosed |
| EP-2621526-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS INC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20180125999-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2018-05-10 | — | — | US | disclosed |
| US-9962454-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2018-04-26 | — | — | US | disclosed |
| EP-2533804-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9926376-B2 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | AGENSYS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925273-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | AGENSYS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9919061-B2 | CD19 binding agents and uses thereof | SEATTLE GENETICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2935331-B1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9878052-B2 | Compounds for targeted immunotherapy | BIRDIE BIOPHARMACEUTICALS INC. (KY) | 2018-01-30 | — | — | US | disclosed |
| US-20180000961-A9 | CD19 BINDING AGENTS AND USES THEREOF | SEAGEN INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2017214456-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214462-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214458-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9827330-B2 | Anti-EGFR antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827329-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-11-28 | — | — | US | disclosed |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-10-12 | — | — | US | disclosed |
| CN-107213469-A | Monomethyl valine compound that can be with ligand coupling | 西雅图基因公司 | 2017-09-29 | — | — | CN | disclosed |
| US-9725515-B2 | Prolactin receptor binding proteins and uses thereof | ABBVIE INC. (US) | 2017-08-08 | — | — | US | disclosed |
| CN-106975082-A | It is incorporated into the antibody drug conjugates (ADC) of 161P2F10B albumen | 艾更斯司股份有限公司 | 2017-07-25 | — | — | CN | disclosed |
| CN-103394083-B | Monomethyl valine compound that can be with ligand coupling | 西雅图基因公司 | 2017-07-18 | — | — | CN | disclosed |
| EP-3189082-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2017-07-12 | — | — | EP | disclosed |
| WO-2017091615-A1 | HUMANIZED ANTI-CLL-1 ANTIBODIES | CELLERANT THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| CN-106563128-A | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mTOR pathway | 西雅图遗传学公司 | 2017-04-19 | — | — | CN | disclosed |
| US-20170072065-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-03-16 | — | — | US | disclosed |
| EP-3134126-A1 | PHARMACEUTICAL FORMULATION OF AN ANTI-GUANYLYL CYCLASE C ANTIBODY CONJUGATE COMPRISING HISTIDINE OR A SALT THEREOF AND POLYSORBATE 20 | Millennium Pharmaceuticals, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| CN-106459200-A | Anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3126006-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170022281-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| EP-3120861-A1 | INTERMEDIATE FOR CONJUGATE PREPARATION COMPRISING AURISTATIN DERIVATIVES AND A LINKER | Seattle Genetics, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2016-12-29 | — | — | US | disclosed |
| US-20160369003-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9522194-B2 | Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160354486-A1 | BINDING MOLECULE CONJUGATES | SEA LANE BIOTECHNOLOGIES, LLC. | 2016-12-08 | — | — | US | disclosed |
| EP-3092254-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HER2 POSITIVE TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2016-11-16 | — | — | EP | disclosed |
| EP-3092256-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | Shanghai Birdie Biotech Inc. (CN) | 2016-11-16 | — | — | EP | disclosed |
| EP-3092255-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING EGFR EXPRESSING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2016-11-16 | — | — | EP | disclosed |
| US-9493568-B2 | Anti-EGFR antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-11-10 | — | — | US | disclosed |
| US-20160319016-A1 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2016-11-03 | — | — | US | disclosed |
| CN-103561759-B | Synergistic effect between AURISTATIN (AURISTATIN) -based antibody drug conjugates and PI3K-AKT mTOR pathway inhibitors | 西雅图遗传学公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20160263243-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | SEAGEN INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160256563-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. | 2016-09-08 | — | — | US | disclosed |
| EP-2478912-B1 | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy | SEATTLE GENETICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2211904-B1 | CD19 BINDING AGENTS AND USES THEREOF | SEATTLE GENETICS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160220693-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC. | 2016-08-04 | — | — | US | disclosed |
| CN-105722534-A | Antibody drug conjugates (ADC) that bind to CD37 proteins | 艾更斯司股份有限公司 | 2016-06-29 | — | — | CN | disclosed |
| EP-3027220-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | Agensys, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9314538-B2 | Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9308278-B2 | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins | AGENSYS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309322-B2 | Antibodies to tumor endothelial marker 8 | SCOTT & WHITE HEALTHCARE (SWH) (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2260858-B1 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| WO-2016034085-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2016-03-10 | — | — | WO | disclosed |
| US-9272052-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEATTLE GENETICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160051694-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | AGENSYS, INC. | 2016-02-25 | — | — | US | disclosed |
| EP-2961424-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | Millennium Pharmaceuticals, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| CN-105142664-A | Administration of an anti-GCC antibody-drug conjugate and a DNA damaging agent in the treatment of cancer | MILLENNIUM PHARM INC | 2015-12-09 | — | — | CN | disclosed |
| US-20150337042-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2015-11-26 | — | — | US | disclosed |
| CN-105073132-A | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | AGENSYS INC | 2015-11-18 | — | — | CN | disclosed |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| WO-2015164581-A1 | PHARMACEUTICAL FORMULATION OF AN ANTI-GUANYLYL CYCLASE C ANTIBODY CONJUGATE COMPRISING HISTIDINE OR A SALT THEREOF AND POLYSORBATE 20 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20150306245-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2486933-B1 | Monomethylvaline compounds conjugated with antibodies | SEATTLE GENETICS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935331-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | AbbVie Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| CN-104998273-A | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC | 2015-10-28 | — | — | CN | disclosed |
| EP-2928503-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | Mersana Therapeutics, Inc. (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150283255-A1 | CD19 BINDING AGENTS AND USES THEREOF | SEATTLE GENETICS INC (US) | 2015-10-08 | — | — | US | disclosed |
| CN-103402538-B | Antibody Drug Conjugates (ADC) that bind to 191P4D12 protein | AGENSYS, INC. (US) | 2015-10-07 | — | — | CN | disclosed |
| WO-2015143382-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-20150238633-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. | 2015-08-27 | — | — | US | disclosed |
| EP-2211885-B1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| WO-2015103990-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING EGFR EXPRESSING TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015103987-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HER2 POSITIVE TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015103989-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2015-07-16 | — | — | WO | disclosed |
| US-9078931-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9073993-B2 | CD19 binding agents and uses thereof | SEATTLE GENETICS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2887959-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | Agensys, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20150174268-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC. (KY) | 2015-06-25 | — | — | US | disclosed |
| EP-2874651-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | Shanghai Birdie Biotech Inc. (CN) | 2015-05-27 | — | — | EP | disclosed |
| CN-104619339-A | Dr5 ligand drug conjugates | SEATTLE GENETICS INC | 2015-05-13 | — | — | CN | disclosed |
| CN-104411329-A | Compounds for targeted immunotherapy | SHANGHAI BODI BIOTECHNOLOGY CO LTD | 2015-03-11 | — | — | CN | disclosed |
| US-8968742-B2 | Antibody drug conjugates (ADC) that bind to 158P1D7 proteins | AGENSYS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150044238-A1 | METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
| WO-2015017552-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | AGENSYS, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150011736-A1 | BINDING MOLECULE CONJUGATES | ALTUS BIOPHARMA INC. | 2015-01-08 | — | — | US | disclosed |
| EP-2489364-B1 | Monomethylvaline compounds conjugated to antibodies | SEATTLE GENETICS INC (US) | 2015-01-07 | — | — | EP | disclosed |
| CN-102573908-B | anti-GCC antibody molecules and compositions and methods related thereto | MILLENNIUM PHARM INC | 2014-12-17 | — | — | CN | disclosed |
| US-20140356383-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. | 2014-12-04 | — | — | US | disclosed |
| EP-2804631-A1 | SURROBODY COJUGATES | Sea Lane Biotechnologies,llc. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20140322233-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | NAM SAMUEL S (US) | 2014-10-30 | — | — | US | disclosed |
| US-8871720-B2 | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| CN-101969970-B | combination therapy with antibody-drug conjugates | SEATTLE GENETICS, INC. (US) | 2014-10-15 | — | — | CN | disclosed |
| WO-2014134311-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20140227294-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140220047-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8785600-B2 | Anti-GCC antibody molecules and related compositions and methods | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140194601-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014105810-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC. (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014093379-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8703714-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| CN-1938046-B | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC | 2014-03-19 | — | — | CN | disclosed |
| US-20140072586-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | SEATTLE GENETICS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2014032021-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| CN-103561759-A | Synergistic effect between AURISTATIN -based antibody drug conjugates and PI3K-AKT mTOR pathway inhibitors | SEATTLE GENETICS INC | 2014-02-05 | — | — | CN | disclosed |
| US-8637642-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | SEATTLE GENETICS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2014012479-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2014-01-23 | — | — | WO | disclosed |
| EP-1725249-B1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8609092-B2 | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins | AGENSYS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130323173-A1 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALT (US) | 2013-12-05 | — | — | US | disclosed |
| CN-103394083-A | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS INC | 2013-11-20 | — | — | CN | disclosed |
| CN-103402538-A | Antibody Drug Conjugates (ADC) that bind to 191P4D12 protein | AGENSYS INC | 2013-11-20 | — | — | CN | disclosed |
| US-8557780-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2637692-A2 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8 | Scott & White Healthcare (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2629801-A2 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | Seattle Genetics, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8512707-B2 | Methods of treating drug-resistant cancers | SEATTLE GENETICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130209496-A1 | Synergistic Effects Between Auristatin-Based Antibody Drug Conjugates And Inhibitors Of The PI3K-AKT mTOR Pathway | Seatle Genetics, Inc. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2621526-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2013109994-A1 | SURROBODY COJUGATES | SEA LANE BIOTECHNOLOGIES, LLC (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20130189286-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | SEATTLE GENETICS (US) | 2013-07-25 | — | — | US | disclosed |
| US-8470329-B2 | Combination therapy with antibody-drug conjugates | SEATTLE GENETICS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130136756-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | SEATTLE GENETICS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130022627-A1 | Combination Therapy With Antibody-Drug Conjugates | SEATTLE GENETICS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2533804-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | Agensys, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120294853-A1 | CD19 Binding Agents and Uses Thereof | SEATTLE GENETICS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8309093-B2 | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins | AGENSYS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8288352-B2 | Auristatins having an aminobenzoic acid unit at the N terminus | SEATTLE GENETICS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8263083-B2 | Combination therapy with antibody-drug conjugates | SEATTLE GENETICS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2490720-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | Millennium Pharmaceuticals, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2489364-A1 | Monomethylvaline compounds onjugated to antibodies | Seattle Genetics, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2486933-A1 | Monomethylvaline compounds conjugated with antibodies | Seattle Genetics, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8242252-B2 | CD19 binding agents and uses thereof | SEATTLE GENETICS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2480230-A2 | DR5 LIGAND DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2478912-A1 | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy | Seattle Genetics, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| CN-102573908-A | anti-GCC antibody molecules and compositions and methods related thereto | MILLENNIUM PHARM INC | 2012-07-11 | — | — | CN | disclosed |
| US-20120148610-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148608-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120141509-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141510-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141508-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012065161-A2 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8 | SCOTT & WHITE HEALTHCARE (US) | 2012-05-18 | — | — | WO | disclosed |
| CN-102448486-A | Antibody Drug Conjugates (ADC) that bind to 24P4C12 protein | AGENSYS INC | 2012-05-09 | — | — | CN | disclosed |
| WO-2012054748-A2 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEATTLE GENETICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012047724-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20120078028-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | SEAGEN INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120034247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120027784-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2403524-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | Agensys, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20120003248-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110312088-A1 | CD19 BINDING AGENTS AND USES THEREOF | SEATTLE GENETICS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110217321-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. | 2011-09-08 | — | — | US | disclosed |
| WO-2011097627-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-7994135-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7968687-B2 | CD19 binding agents and uses thereof | SEATTLE GENETICS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7964566-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964567-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110110936-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| WO-2011050242-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011038159-A2 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20110070248-A1 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| CN-101969970-A | Combination therapy with antibody-drug conjugates | SEATTLE GENETICS INC | 2011-02-09 | — | — | CN | disclosed |
| US-20100330107-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2260858-A2 | Monomethylvaline compounds capable of conjugation to ligands | Seattle Genetics, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100260786-A1 | METHODS OF TREATING DRUG-RESISTANT CANCERS | SEATTLE GENETICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010111018-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100215671-A1 | Combination Therapy With Antibody-Drug Conjugates | SEAGEN INC. | 2010-08-26 | — | — | US | disclosed |
| EP-2211885-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2211904-A2 | CD19 BINDING AGENTS AND USES THEREOF | Seattle Genetics, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| US-7750116-B1 | Antibody drug conjugate metabolites | SEATTLE GENETICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7745394-B2 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100040637-A1 | Methods and Composition for Treating Diseases Targeting Prominin-1 (CD133) | Celera Corporation | 2010-02-18 | — | — | US | disclosed |
| US-20090136526-A1 | CD19 Binding Agents and Uses Thereof | SEATTLE GENETICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090111756-A1 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus | SEATTLE GENECTICS, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2009052431-A2 | CD19 BINDING AGENTS AND USES THEREOF | SEATTLE GENETICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009048967-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-7498298-B2 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20080305044-A1 | Engineered Antibodies and Immunoconjugates | SEATTLE GENETICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080300192-A1 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus | SEATTLE GENETICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007137170-A2 | ANTI-GLYPICAN-3 ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007103288-A2 | ENGINEERED ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1817341-A2 | ENGINEERED ANTIBODIES AND IMMUNOCONJUGATES | Seattle Genetics, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1817336-A2 | AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS | Seattle Genetics, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007062138-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES TARGETING HUMAN PROMININ-1(CD133) | APPLERA CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
| CN-1938046-A | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC (US) | 2007-03-28 | — | — | CN | disclosed |
| WO-2007008848-A2 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006132670-A2 | AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS | SEATTLE GENETICS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1725249-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seattle Genetics, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006065533-A2 | ENGINEERED ANTIBODIES AND IMMUNOCONJUGATES | SEATTLE GENETICS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | GSR 2598/4885CPB2 1810/4885ITGB3 1127/4885 |
| US-20190134216-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | GSR 4668/4885CPB2 3591/4885ITGB3 248/4885 |
| US-20160256563-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | CD2BP2, IGSF11, EPB41L2 | GSR 4861/4885CPB2 1315/4885ITGB3 50/4885 |
| US-20190269790-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | GSR 2234/4885CPB2 2948/4885ITGB3 2614/4885 |
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | GSR 2598/4885CPB2 1810/4885ITGB3 1127/4885 |
| US-20090111756-A1 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus | MMAB, PTMS, CAD | GSR 3106/4885CPB2 621/4885ITGB3 2013/4885 |
| US-20230069760-A1 | ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | VSIG8, VMP1, VSIR | GSR 4643/4885CPB2 4585/4885ITGB3 1518/4885 |
| US-20220288221-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | GSR 4668/4885CPB2 3591/4885ITGB3 248/4885 |
| US-20160051694-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | SIGLEC7, FUT7, SLC17A5 | GSR 4786/4885CPB2 3321/4885ITGB3 104/4885 |
| US-20160263243-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, ADCK5 | GSR 4869/4885CPB2 1964/4885ITGB3 1271/4885 |
| US-20150283255-A1 | CD19 BINDING AGENTS AND USES THEREOF | BCL6B, CD22, BCL6 | GSR 4868/4885CPB2 565/4885ITGB3 1426/4885 |
| US-11607460-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | GSR 4205/4885CPB2 4073/4885ITGB3 589/4885 |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | GSR 4870/4885CPB2 4366/4885ITGB3 76/4885 |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | GSR 3843/4885CPB2 1766/4885ITGB3 1043/4885 |
| US-10744206-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | GSR 2234/4885CPB2 2948/4885ITGB3 2614/4885 |
| US-20140227294-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | PRLHR, LHCGR, FCGR2A | GSR 3334/4885CPB2 1421/4885ITGB3 1859/4885 |
| US-20140356383-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | OGG1, ERCC5, ERCC2 | GSR 887/4885CPB2 1649/4885ITGB3 3497/4885 |
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | MTOR, RICTOR, PIK3R5 | GSR 4205/4885CPB2 4073/4885ITGB3 589/4885 |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | CD47, CD274, TP53 | GSR 2234/4885CPB2 2948/4885ITGB3 2614/4885 |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | MMAB, CAD, TRIM59 | GSR 1818/4885CPB2 1671/4885ITGB3 1339/4885 |
| US-20180355044-A1 | HUMANIZED ANTI-CLL-1 ANTIBODIES | BCL9L, BCL9, BCL6B | GSR 4760/4885CPB2 3013/4885ITGB3 695/4885 |
| US-11633494-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | GSR 2234/4885CPB2 2948/4885ITGB3 2614/4885 |
| US-20210402002-A1 | CONJUGATE | ST6GAL1, CSGALNACT1, FUT6 | GSR 2759/4885CPB2 440/4885ITGB3 2101/4885 |
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | GSR 2052/4885CPB2 2696/4885ITGB3 1796/4885 |
| US-20220389113-A1 | BINDING PROTEINS TO CUB DOMAIN-CONTAINING PROTEIN (CDCP1) | CD2BP2, CDC5L, CDCA2 | GSR 4547/4885CPB2 687/4885ITGB3 1892/4885 |
| US-20180236096-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS | SIGLEC7, FUT7, SLC17A5 | GSR 4786/4885CPB2 3321/4885ITGB3 104/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | GSR 4698/4885CPB2 3644/4885ITGB3 400/4885 |
| US-20120148610-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | GSR 2598/4885CPB2 1810/4885ITGB3 1127/4885 |
| US-10184003-B2 | Prolactin receptor binding proteins and uses thereof | PRLHR, LHCGR, FCGR2A | GSR 3334/4885CPB2 1421/4885ITGB3 1859/4885 |
| US-10941211-B2 | Anti-GCC antibody molecules and related compositions and methods | CD2BP2, UACA, COPG2 | GSR 4724/4885CPB2 1430/4885ITGB3 2048/4885 |
| US-20230001005-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | CD2BP2, IGSF11, PA2G4 | GSR 4822/4885CPB2 1269/4885ITGB3 2001/4885 |
| US-20130323173-A1 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8 | VAMP8, LENG8, TMED7 | GSR 4741/4885CPB2 948/4885ITGB3 338/4885 |
| US-11331394-B2 | CD19 binding agents and uses thereof | CD22, CD2BP2, BCL6B | GSR 4883/4885CPB2 477/4885ITGB3 652/4885 |
| US-20180177888-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | PBK, CD4, CD47 | GSR 4315/4885CPB2 3785/4885ITGB3 651/4885 |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | LGALS3BP, PABPC4, PA2G4 | GSR 4783/4885CPB2 2733/4885ITGB3 315/4885 |
| US-20180177887-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | PBK, CD4, CD47 | GSR 4315/4885CPB2 3785/4885ITGB3 651/4885 |
| US-10226535-B2 | Auristatin compounds and conjugates thereof | PBRM1, AURKB, ILK | GSR 4430/4885CPB2 1767/4885ITGB3 1459/4885 |
| US-20180296693-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, ADCK5 | GSR 4869/4885CPB2 1964/4885ITGB3 1271/4885 |
| US-20170072065-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | GSR 4668/4885CPB2 3591/4885ITGB3 248/4885 |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | GSR 4870/4885CPB2 4366/4885ITGB3 76/4885 |
| US-20180355062-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | CD2BP2, UACA, COPG2 | GSR 4724/4885CPB2 1430/4885ITGB3 2048/4885 |
| US-20220227863-A1 | ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ILF3, ILF2, IKZF3 | GSR 4829/4885CPB2 4754/4885ITGB3 62/4885 |
| US-20210138080-A1 | CONJUGATES | LGALS1, LGALS3BP, LGALS2 | GSR 2706/4885CPB2 204/4885ITGB3 755/4885 |
| US-10201615-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | GSR 4205/4885CPB2 4073/4885ITGB3 589/4885 |
| US-11559582-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | IGSF11, CD2BP2, ADCK5 | GSR 4869/4885CPB2 1964/4885ITGB3 1271/4885 |
| US-20200179527-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | PBK, CD4, CD47 | GSR 4315/4885CPB2 3785/4885ITGB3 651/4885 |
| US-20220175950-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | TMED10, CD44, CA12 | GSR 4849/4885CPB2 1817/4885ITGB3 2602/4885 |
| US-10548985-B2 | Compounds and compositions for treating EGFR expressing tumors | EGFR, ERBB2, ERBB3 | GSR 3462/4885CPB2 2504/4885ITGB3 1011/4885 |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | ERBB2, EGFR, TP53 | GSR 3474/4885CPB2 2261/4885ITGB3 1519/4885 |
| US-11434303-B2 | Anti-LY6H antibodies and antibody drug conjugates | LY6K, LY96, CD74 | GSR 4740/4885CPB2 4069/4885ITGB3 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.